Review the Regulation of Plasma Membrane Calcium Channel in Cancer and Patch Clamp Technique

Nanjun Chen¹, *, a, †, Qigeng Fang ², b, †

¹School of Biological Science, University of Edinburgh, Edinburgh city, EH91PH, The United Kingdom; ²Lakehead University, Thunder Bay, Ontario, P7B5E1, Canada;
†These authors contributed equally.

Abstract. As one of the most versatile and universal second messengers, calcium plays an essential role in cell life. Here we briefly reviewed the research progress of how different calcium channels are located at the cell plasma membrane, including voltage-gated calcium channels (VGCCs), receptor-operated channels (ROC), and store-operated channels (ROC). These channels can regulate different cancer progression. Afterward, the patch clamp technique's development and operating principle, an important quantitative method used for ion channel investigation, are introduced in this paper.

1 Introduction

Calcium (Ca²⁺), known as a versatile and universal second messenger, is selected by a long course of organic evolution. It can transduce extracellular signaling and intracellular signaling to regulate numerous enzymes and proteins and further contribute to a wide range of cellular activity. Such universal cellular activities include fertilization, embryonic development, differentiation, transcription factor regulation, apoptosis, autophagy, cancer, and even virus infection [1-4]. The uniqueness of Ca²⁺ signaling is determined by its unique concentration gradient distribution among extracellular, cytosolic, and the endoplasmic reticulum (ER) in resting state. This feature gives Ca²⁺ the ability to regulate cellular processes in diverse spatio-temporal patterning, amplitude, and waves [1]. The history of scientists targeting calcium channels for disease treatment can be traced back to the 1960s, when the therapeutic effect of dihydropyridine molecules in cardiovascular disease was found [5]. In the last half century, great efforts have been put into studying how to target calcium channels for clinical therapy. Recently, more and more evidence suggest the calcium channels would be potential drug targets for cancer therapy, and Ca²⁺ signaling regulates cancer development in several aspects. Moreover, several Ca²⁺ channel inhibitors can efficaciously restrain the cell growth in human melanoma, colon carcinoma, prostate cancer, etc. [6,7]. Here, we intend to focus on the latest research advances about Ca²⁺ signaling regulation in cancer and reveal the mechanism of those regulations as well as patch clamp technique, the most common quantitative detection method for Ca²⁺.

2 Role of Ca²⁺ Channels in Cancer

Tumorigenesis is caused by mutation whereby normal cells are endowed with cancer-specific hallmarks, including self-sufficiency in growth signals, insensitivity to anti-growth signals, and evading apoptosis, etc. [8]. Since versatile Ca²⁺ signal precisely controls numerous cell activities with widely different spatial and temporal profiles [9], the function of Ca²⁺ channels in various tumor cells is also particularly important. The plasma membrane (PM) calcium channels/transporters serve as the outermost gates to maintain the cytosolic [Ca²⁺] rapidly by controlling the influx of extracellular Ca²⁺ or extruding the intercellular Ca²⁺, thus keeping the homeostasis together with those intercellular calcium channels. So, here comes a significant question: how plasma membrane Ca²⁺ channels contribute to the intercellular calcium homeostasis, and how broken homeostasis led to cancer development. It is acknowledged that cell proliferation is closely related to the cell cycle. The cell cycle contains four primary phases, which are G1 phase, S phase (DNA synthesis), G2 phase, and M phase (or mitosis). The checkpoint between each phase strictly controls the phase transition, and it was reported that calcium signaling participates in each phase and the cell circle checkpoint. The dysfunction of upstream PM Ca²⁺ signaling pathways can affect the downstream signaling pathways and change normal cell proliferation.
**3 Ca²⁺ Channels on plasma membrane**

### 3.1 Voltage-gated Calcium Channels

The Voltage-gated calcium channels (VGCCs) are a group of channels mainly permeable to calcium ions in response to depolarized membrane potential [10]. Currently, there are five subtypes of VGCCs been recognized to include the L(Long-lasting)-type, N(Neural)-type, R(Residual)-type, T-type, and P(Purkinje)-/Q-type. Because the different subtypes of VGCCs take charge of different cell functions such as synapse transmission, mitotic signaling, and cell cycle progression [11], they synergistically contribute to cancer cells' proliferation. It is reported that the α1 subunit of the protein constructs the ion-selective pore, and different VGCC subtypes contain α1 subunit encoded by ten various genes in humans (as it shows in Table 1).

The function of low voltage-activated T-type VGCCs in cancer progression was studied at a very early stage. In the first place, people pay less attention to the role of VGCCs in breast cancer due to such cancer cells are non-excitable cells in which the influence of VGCCs was less regarded [25]. Nowadays, it is acknowledged that VGCCs are expressed in various non-excitable cells such as breast cells, kidney cells, and prostate cells. The overexpression of encoded gene CACNA1G was found to be capable of inhibiting proliferation in α1 subunit encoded by ten various genes in humans (as it shows in Table 1).

**Table 1: Different VOC α1 Subunit Genes and Their Associated Cancer Types**

| VOC Type | Activated Voltage | α1 Subunit Gene | Significant Associated Cancer | References |
|----------|------------------|----------------|-------------------------------|------------|
| L-Type   | High Voltage Activated (HVA) | CACNA1S (Cav1.1) | Renal, Head-neck | [12] [13] |
|          |                   | CACNA1C (Cav1.2) | Brain, Lymphoma, Prostate, Renal | [14] [15] [16] |
|          |                   | CACNA1D (Cav1.3) | Lung, Renal | [17] [16] |
|          |                   | CACNA1F (Cav1.4) | Lymphoma | [15] |
| P-/Q-Type|                   | CACNA1A (Cav2.1) | Brain, Esophagus, Breast | [18] [19] [20] |
| N-Type   | Medium Voltage Activated | CACNA1B (Cav2.2) | Brain, Male breast | [18] [21] |
| R-Type   |                   | CACNA1E (Cav2.3) | Gastric, Prostate | [22] |
| T-Type   | Low Voltage Activated (LVA) | CACNA1G (Cav3.1) | Ovarian | [23] |
|          |                   | CACNA1H (Cav3.2) | Brain, Bladder | [22] [24] |
|          |                   | CACNA1I (Cav3.3) | Brain, Breast | [22] |

In the L-type (Cav1) family, most evidence indicates the mutation of the CACNA1D gene is responsible for prostate cancer and adrenal aldosterone-producing adenomas (APA) [30]. The significant over-expression of the CACNA1D gene is associated with the transactivation of androgen receptor and malignant prostate cancer [31]. The channel's abnormal expression exhibits in various cancers such as acute myeloid leukaemia and squamous cell carcinoma (CACNA1S overexpress). Meanwhile, it is downregulated in renal oncocytoma and squamous cell lung carcinoma (CACNA1S down-expression). Moreover, the downregulation of the CACNA1C gene in L-type is mainly responded to most brain tumour types [32].

The bioinformatic analysis also suggested that CACNA1A encoded P-/Q-type VGCC α1 subunit specifically had low expression in colorectal, esophageal, and gastric cancers. Hence, the potential of P-/Q-type VGCC as a drug target for those cancers are worth further research [32].

### 3.2 Receptor-operated Channels

Receptor-operated calcium channels (ROCC) are referred to as the non-voltage-gated Ca²⁺ channels, which can be regulated by a series of G-protein-coupled receptors on the plasma membrane [33]. Recently, the role of these channels in cancer progression is increasingly appreciated.

P2 receptors are Ca²⁺, Na⁺, and K⁺ permeable ion channels gated by ATP. This property endowed them with distinct functions in cancer development. Since
Table 2: Different TRP Channel Subtypes and Associated Cancer Types

| Subfamily          | Subtype | Cancer Type                                      | References |
|--------------------|---------|-------------------------------------------------|------------|
| TRPC (Canonical)   | TRPC1   | Glioma, lung carcinoma, Nasopharyngeal carcinoma | [49] [50] [51] |
|                    | TRPC3   | Ovarian cancer                                  | [52]       |
|                    | TRPC5   | Breast cancer                                    | [53]       |
|                    | TRPC6   | Gastric cancer                                  | [54]       |
| TRPM (Melastatin)  | TRPM1   | Melanoma                                        | [55]       |
|                    | TRPM2   | Prostate cancer                                 | [55]       |
|                    | TRPM4   | Prostate cancer                                 | [56]       |
|                    | TRPM7   | Breast, Lung, Pancreatic cancer, Nasopharyngeal carcinoma | [57] [45] |
|                    | TRPM8   | Breast, Lung, Prostate cancer                   | [57]       |
| TRPV (Vanilloid)   | TRPV1   | Breast cancer                                    | [48]       |
|                    | TRPV2   |                                                 |            |
|                    | TRPV6   |                                                 |            |
|                    | TRPV4   | Gastric, Lung, etc.                             | [58] [59]  |

There is extracellular ATP (eATP) enrichment in the tumour microenvironment, Adinolfi et al. summarized that the P2 receptor subtype P2X receptor plays an important role in the differentiation, angiogenesis, and migration of tumour cells in 2015 [34]. Some then suggested that the activation of the P2X7 receptor could reduce the PI3K/Akt activity and participate in neuroblastoma progression [35]. It was also reported that the P2X receptor can act as Neoplastic ATP pipeline, thus refueling eATP into tumour interstitium [36]. Based on these findings, the P2X family could be a potential target for developing innovative cancer therapy.

The N-methyl-D-aspartate receptor (NMDA receptor) is another important ROC that contributes to intercellular calcium homeostasis. NMDA receptor is another drug target for cancer therapy because it regulates the mTOR signaling activity, hence modulate the metabolism, autophagy, and apoptosis of several cancer cell lines (e.g., gastric tumors, glioblastoma, small cell lung cancer, etc.) [37].

3.3 Store-operated Calcium Channels

As the VOC/ROC can be activated during the membrane depolarize in excitatory cells, the Store-operated calcium channels (SOCC) regulate the Ca^{2+} influx in various non-excitable cells [38]. The store-operated Ca^{2+} entry (SOCE) process is generally regulated by the intercellular calcium store, such as the endoplasmic reticulum (ER) and sarcoplasmic reticulum (SR). This activity can regulate the insensitivity to antigrowth signals. So unsurprisingly, it was reported that among the SOCCs, several members in the transient receptor potential (TRP) channels superfamily are significant in cell proliferation and cancer progression [39] [40]. Another important SOCC network is the OARAI-STIM proteins, which are also reported to play crucial roles in cancer development.

It is acknowledged that the TRP superfamily is consist of 2 main groups and can be subdivided into nine subfamilies in animal, which are: TRPC, TRPN, TRPS, TRPM, TRPV, TRPVL, and TRPA in group one and TRPP, TRPML in group two according to the cladogram [41]. Normally, TRP channels respond to various stimuli like temperature and mechanical stress [42]., they are also reported to be influential to calcium homeostasis and cell cycle [22] [43]. So far, it is recognized that the TRPC, TRPM, and TRPV families are closely associated with cancer progression. As shown in Figure 2, the TRPC family reported being capable of presenting diagnostic markers in the progression of human ovarian cancer and nasopharyngeal carcinoma [44] [45]. Meanwhile, the TRPM family is identified to promote several cancer, especially prostate cancer [46] [47]. Moreover, the TRPM subfamily is identified to promote prostate cancer, pancreatic cancer, lung cancer, etc. Furthermore, convicive evidence suggests expression change of several members in the TRPV subfamily are associated with the progression of breast cancer [48].

There are also increasing studies targeting ORAI-STIM in the SOCC family as novel cancer therapy targets in recent years, ORAI1,3 and STIM1,2 (stromal interaction molecules) meditate the so-called store-operated calcium entry, and the structural biology of these two molecules determined their special operation mode. The STIM1 protein contains transmembrane domains include a canonical EF hand, a hidden EF hand, and the sterile alpha motif (SAM) domain inside the ER lumen. They operated as a calcium concentrate sensor [60]. Once the intracellular stores are depleted, the STIM1 molecules will oligomerize immediately and interact with ORAI to link the organelle and PM. ORAI will then inject calcium ions into corresponding
organelles [61]. In breast cancer, some suggested the ORAI-STIM meditated SOCE plays a crucial role in cell migration [62]. Moreover, the up regulation of ORAI and STIM also impact tumour growth and migration in several cancers, such as breast cancer, prostate cancer, colorectal cancer, cervical cancer, brain tumours, etc. [63].

4 Patch Clamp Technique the Essential Quantitative Methodology

The patch clamp technique, developed in the late 1970s, has become an indispensable tool in Ca²⁺ channel studies. In actual research work, it plays an important role in detecting calcium ion channels are antagonized or excited. It can accurately measure ion channel current. The patch clamp's basic principle is to isolate a single ion channel from the membrane by a micropipette and then measure the channel current. The key point is to form a high-resistance seal (up to 10 - 100 GΩ) between the cell membrane and the micropipette [64]. Inside the micropipette are a single ion channel and an electrode so that the channel current will not leak outside but totally flow to the electrode. A tiny ionic current will be monitored by the electrode when ions pass through the ion channel. And then, the current will be amplified into a measurable value. In this section, the configurations of the conventional patch clamp are presented first. Then, some newly developed techniques for patch clamp are reviewed.

4.1 Conventional patch clamp

A conventional patch clamp system consists of a micropipette and an amplifier circuit. According to the attachment configuration between the micropipette tip and cell membrane, the patch clamp can be divided into four modes. The simplest mode is the cell-attached mode, as shown in Fig.1. The micropipette first attaches the cell membrane. Then a negative pressure is applied in the micropipette to form a GΩ seal. The single ion channel surrounded by the tip of the micropipette can be studied. However, the membrane potential is unknown and cannot be measured through this configuration. Based on cell-attached patch mode, if a higher negative pressure is applied so that the membrane under the pipette tip is broken, the cytoplasm will be directly contacted with the pipette solution. This mode is called whole-cell mode. Under this mode, the total currents of all ion channels can be directly measured and recorded.

In addition, there are two cell-free modes called inside-out excised patch and outside-out excised patch, as shown in Fig.2. The inside-out patch is obtained by pulling away the micropipette from a cell-attached configuration. Similarly, the outside-out patch is obtained by pulling away the micropipette from a whole-cell configuration. Table 3 summarizes the advantages and disadvantages of these two configurations.

To study the ion channel behaviour and properties in detail, quantitative researches are necessary. According to the electric circuit's configuration and the working principle, patch clamp can be classified into two different types: voltage clamp and current clamp. Voltage clamp can keep cell membrane potential unchanged while recording the membrane current. A constant current is injected through the pipette electrode for the current clamp, and the changing voltage is recorded. Voltage clamp is more widely used in Ca²⁺ channel studies. Fig. 3 shows the configuration of the voltage clamp. It always consists of a negative feedback amplifier (A1) and a differential amplifier (A2). Generally, $R_f$ is extremely large and much larger than $R$, so $V_o$ can be roughly equal to $IR_f$. It can be seen that
through the voltage clamp circuit, an extremely small membrane current is amplified to a measurable level.

### Table 3: Summary of Inside-out and Outside-out Configurations

| Configuration | Advantages | Disadvantages |
|---------------|------------|---------------|
| Inside-out    | Extracellular environment is controlled. Good way to study the effects of intracellular factors on ion channels. | Washout of cytosolic factors. Destruction of cell structure. Bath solution must be similar with the Cytosolic environment. |
| Outside-out   | Cytosolic environment is controlled. Good way to study the effects of extracellular factors on ion channels. | Washout of cytosolic factors. Destruction of cell structure. Micropipette solution must be similar with the Cytosolic environment. |

**Fig 3.** Voltage clamp configuration

### 4.2 Automated patch clamp techniques

Conventional patch clamp techniques have some inevitable disadvantages [67] [68]. For example, the operations are time-consuming and very difficult. Operators need to micromanipulate a micropipette under a microscope to record the membrane current from one cell at a time. So that the throughput will be very low. What’s more, the intracellular solution cannot be changed easily during the experiments. Therefore, for some particular researches, the patch clamp has to work in many different modes, and a large number of experiments need to be done.

To overcome these disadvantages, scientists have developed automated patch clamp techniques. Lepple-Wienhues A, Ferlinz K, Seeger A, et al. (2003) [69] presented an automated patch clamp technology called “flip the tip”. In this method, the micropipette is filled with cell suspension. The suspended cells in the micropipette solution will be automatically flushed to the micropipette tip and form a high-resistance seal, as shown in Fig. 4. Compared with the conventional method, this method is much easier to operate. Moreover, a microscope and micromanipulator are no longer needed.

**Fig 4.** Conventional patch clamp (left) and “flip the tip” technology (right) [69]

Scientists also developed a planar patch clamp, which replaces the micropipette with a quartz chip with a small aperture. It was reported by Niels Fertig, Robert H. Blick and Jan C. Behrends (2002) [70]. Fig. 5 shows the configuration of the planar patch clamp. The cell suspension is given on the chip surface. The cell will automatically move to the aperture through an electric field or a negative pressure. Then, light suction is applied to absorb the cell and automatically form a high-resistance seal. Microscope and micromanipulator are also not needed in this method. Based on this planar patch clamp technique, Finkel et al. (2006) presented the population patch clamp technique [71], as shown in Fig. 6. The average current of multiple cells in a single well is recorded by a voltage-clamp. And the current in each well is measured at the same time. This method highly increases data consistency.

**Fig 5.** Planar patch clamp configuration [70]
5 Conclusion

The regulation of calcium signaling is a super complicated system and has been studied by scholars all the time. In this paper, we generally reviewed the recent findings on several plasma membrane Ca\(^{2+}\) channels in cancer progression. With the support of more and more basic research and advanced bioinformatic techniques, the therapeutic potential of these Ca\(^{2+}\) channels has entered people's vision. However, many further investigations are required to verify whether these channels are ideal novel therapy targets in different cancer subdivisions. In addition, we also introduce the circuitry and principle of patch clamp techniques. The development of the automated patch clamp technique greatly liberated researchers' productivity, allowing them to invest more effort in targets identification.

References

1. M. J. Berridge, P. Lipp, and M. D. Bootman, "The versatility and universality of calcium signalling," Nat. Rev. Mol. Cell Biol., vol. 1, no. 1, pp. 11–21, 2000, doi: 10.1038/35036035.

2. M. D. Bootman, T. Chehab, G. Bultynck, J. B. Parys, and K. Rietdorf, "The regulation of autophagy by calcium signals: Do we have a consensus?," Cell Calcium, vol. 70, no. August 2017, pp. 32–46, 2018, doi: 10.1016/j.cca.2017.08.005.

3. C. Cui, R. Merritt, L. Fu, and Z. Pan, "Targeting calcium signaling in cancer therapy," Acta Pharm. Sin. B, vol. 7, no. 1, pp. 3 – 17, 2017, doi: 10.1016/j.apsb.2016.11.001.

4. Y. Zhou, T. K. Frey, and J. J. Yang, "Viral calcimics: Interplays between Ca\(^{2+}\) and virus," Cell Calcium, vol. 46, no. 1, pp. 1–17, 2009, doi: 10.1016/j.cca.2009.05.005.

5. T. Godfraind, "Discovery and Development of Calcium Channel Blockers," Front. Pharmacol., vol. 8, May 2017, doi: 10.3389/fphar.2017.00286.

6. W. Lewis, "Clotrimazole inhibits cell proliferation in vitro and in vivo," Nat. Med., vol. 1, no. 5, pp. 1–6, 1995.

7. D. M. Haverstick, T. N. Heady, T. L. Macdonald, and L. S. Gray, "Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca\(^{2+}\) entry1," Cancer Res., vol. 60, no. 4, pp. 1002–1008, 2000.

8. D. Hanahan and R. A. Weinberg, "The Hallmarks of Cancer," Cell, vol. 100, no. 1, pp. 57–70, Jan. 2000, doi: 10.1016/S0092-8674(00)81683-9.

9. M. J. Berridge, P. Lipp, and M. D. Bootman, "The versatility and universality of calcium signalling," Nat. Rev. Mol. Cell Biol., vol. 1, no. 1, pp. 11–21, Oct. 2000, doi: 10.1038/35036035.

10. W. A. Catterall, E. Perez-Reyes, T. P. Snutch, and J. Striessnig, "International Union of Pharmacology. XLVIII. Nomenclature and Structure-Function Relationships of Voltage-Gated Calcium Channels," Pharmacol. Rev., vol. 57, no. 4, pp. 411–425, Dec. 2005, doi: 10.1124/pr.57.4.5.

11. V. R. Rao, M. Perez-Neut, S. Kaja, and S. Gentile, "Voltage-Gated Ion Channels in Cancer Cell Proliferation," Cancers, vol. 7, no. 2, Art. no. 2, Jun. 2015, doi: 10.3390/cancers7020813.

12. J. Jones et al., "Gene Signatures of Progression and Metastasis in Renal Cell Cancer," Clin. Cancer Res., vol. 11, no. 16, pp. 5730–5739, Aug. 2005, doi: 10.1158/1078-0432.CCR-04-2225.

13. M. A. Ginos et al., "Identification of a Gene Expression Signature Associated with Recurrent Disease in Squamous Cell Carcinoma of the Head and Neck," Cancer Res., vol. 64, no. 1, pp. 55–63, Jan. 2004, doi: 10.1158/0008-5472.CAN-03-2144.

14. C.-Y. Wang, M.-D. Lai, N. N. Phan, Z. Sun, and Y.-C. Lin, "Meta-Analysis of Public Microarray Datasets Reveals Voltage-Gated Calcium Gene Signatures in Clinical Cancer Patients," PLOS ONE, vol. 10, no. 7, p. e0125766, Jul. 2015, doi: 10.1371/journal.pone.0125766.

15. J.-Y. Zhang et al., "L-Type Cav. 1.2 Calcium Channel-α1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma," Clin. Cancer Res., vol. 25, no. 13, pp. 4168–4178, Jul. 2019, doi: 10.1158/1078-0432.CCR-18-2146.

16. M. V. Yusenko, R. P. Kuiper, T. Boethe, B. Ljungberg, A. G. van Kessel, and G. Kovacs, "High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas," BMC Cancer, vol. 9, p. 152, May 2009, doi: 10.1186/1471-2407-9-152.

17. C. Cui, R. Merritt, L. Fu, and Z. Pan, "Targeting calcium signaling in cancer therapy," Acta Pharm. Sin. B, vol. 7, no. 1, pp. 3–17, Jan. 2017, doi: 10.1016/j.apsb.2016.11.001.
18. S. L. Pomeroy et al., "Prediction of central nervous system embryonal tumour outcome based on gene expression," Nature, vol. 415, no. 6870, Art. no. 6870, Jan. 2002, doi: 10.1038/415436a.

19. Y. Hao, G. Triadafilopoulos, P. Sahbaie, H. S. Young, M. B. Omary, and A. W. Lowe, "Gene Expression Profiling Reveals Stromal Genes Expressed in Common Between Barrett’s Esophagus and Adenocarcinoma," Gastroenterology, vol. 131, no. 3, pp. 925 – 933, Sep. 2006, doi: 10.1053/j.gastro.2006.04.026.

20. G. Tarashvili et al., "Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis," BMC Cancer, vol. 7, p. 55, Mar. 2007, doi: 10.1186/1471-2407-7-55.

21. X. Zhou et al., "CACNA1B (Cav2.2) Overexpression and Its Association with Clinicoopathologic Characteristics and Unfavorable Prognosis in Non-Small Cell Lung Cancer," Disease Markers, Jan. 03, 2017. https://www.hindawi.com/journals/dm/2017/613640/ (accessed Jan. 08, 2021).

22. H. L. Roderick and S. J. Cook, "Ca 2+ signalling checkpoints in cancer: remodelling Ca 2+ for cancer cell proliferation and survival," Nat. Rev. Cancer, vol. 8, no. 5, Art. no. 5, May 2008, doi: 10.1038/nrc2374.

23. L. Antal and M. Martin-Caraballo, "T-type Calcium Channels in Cancer," Cancers, vol. 11, no. 2, Jan. 2019, doi: 10.3390/cancers11020134.

24. J.-S. Lee et al., "Expression Signature of E2F1 and Its Associated Genes Predict Superficial to Invasive Progression of Bladder Tumors," J. Clin. Oncol., vol. 28, no. 16, pp. 2660 – 2667, Apr. 2010, doi: 10.1038/jco.2009.23274.

25. I. Azimi, S. J. Roberts-Thomson, and G. R. Monteith, "Calcium influx pathways in breast cancer: opportunities for pharmacological intervention," Br. J. Pharmacol., vol. 171, no. 4, pp. 945–960, Feb. 2014, doi: 10.1111/bph.12486.

26. T. Ohkubo and J. Yamazaki, "T-type voltage-activated calcium channel Cav3.1, but not Cav3.2, is involved in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells," Int. J. Oncol., vol. 41, no. 1, pp. 267–275, Jul. 2012, doi: 10.3892/ijo.2012.1422.

27. J. T. Taylor et al., "Selective blockade of T-type Ca2+ channels suppresses human breast cancer cell proliferation," Cancer Lett., vol. 267, no. 1, pp. 116–124, Aug. 2008, doi: 10.1016/j.canlet.2008.03.032.

28. B. Dziegielewksa, L. S. Gray, and J. Dziegielewski, "T-type calcium channels blockers as new tools in cancer therapies," Pflüg. Arch. - Eur. J. Physiol., vol. 466, no. 4, pp. 801 – 810, Apr. 2014, doi: 10.1007/s00424-014-1444-z.

29. N. C. K. Valerie et al., "Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells," Biochem. Pharmacol., vol. 85, no. 7, pp. 888–897, Apr. 2013, doi: 10.1016/j.bcp.2012.12.017.

30. U. I. Scholl et al., "Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism," Nat. Genet., vol. 45, no. 9, pp. 1050–1054, Sep. 2013, doi: 10.1038/ng.2695.

31. R. Chen et al., "Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers" This work was partially supported by grants from DoD PCRP program (W81XWH-09-1-0455) and KUMC Valk Foundation to Dr Benyi Li, and grants from China Natural Science Foundation to Dr Benyi Li (NSFC #81172427) and Dr Jun Yang (NSFC #81101927). This project was also supported by the ‘Chutian Scholar’ program funded by Hubei Province of China dedicated to China Three Gorges University.," Urol. Oncol. Semin. Orig. Investig., vol. 32, no. 5, pp. 524 – 536, Jul. 2014, doi: 10.1016/j.urolonc.2013.05.011.

32. N. N. Phan, C.-Y. Wang, C.-F. Chen, Z. Sun, M.-D. Lai, and Y.-C. Lin, "Voltage-gated calcium channels: Novel targets for cancer therapy," Oncol. Lett., vol. 14, no. 2, pp. 2059 – 2074, Aug. 2017, doi: 10.3892/ol.2017.6457.

33. I. McFadzean and A. Gibson, "The developing relationship between receptor-operated and store-operated calcium channels in smooth muscle," Br. J. Pharmacol., vol. 135, no. 1, pp. 1–13, Jan. 2002, doi: 10.1038/sj.bjp.0704468.

34. E. Adinolfi, M. Capece, F. Amoroso, E. De Marchi, and A. Franceschini, "Emerging roles of P2X receptors in cancer," Curr. Med. Chem., vol. 22, no. 13, Jan. 2002, doi: 10.2174/0929867321666141012172913.

35. F. Amoroso et al., "The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signalling network: evidence in experimental neuroblastoma," Oncogene, vol. 34, no. 41, Art. no. 41, Oct. 2015, doi: 10.1038/onc.2014.444.

36. D. V. Francesco, V.-P. Valentina, and C. Alba, "P2X receptors in cancer growth and progression," Biochem. Pharmacol., p. 114350, Nov. 2020, doi: 10.1016/j.bcp.2020.114350.

37. S. I. Deutsch, A. H. Tang, J. A. Burket, and A. D. Benson, "NMAD receptors on the surface of cancer cells: Target for chemotherapy?," Biomed. Pharmacother., vol. 68,
no. 4, p. 493, May 2014, doi: 10.1016/j.bioph.2014.03.012.
38. A. B. Parekh and J. W. Putney, "Store-Operated Calcium Channels," Physiol. Rev., vol. 85, no. 2, pp. 757 – 810, Apr. 2005, doi: 10.1152/physrev.00057.2003.
39. S. Thebault et al., "Differential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cells," Cancer Res., vol. 66, no. 4, pp. 2038–2047, Feb. 2006, doi: 10.1158/0008-5472.CAN-05-0376.
40. E. B. Charbel, B. Gabriel, and E. Antoine, "Capacitative calcium entry and transient receptor potential canonical 6 expression control human hepatoma cell proliferation - El Boustany," vol. Vol. 47, p. p.2068-2077, Feb. 2008, doi: 10.1002/hep.22263.
41. J. H. Nathaniel and N. C. Daniel, "Transient receptor potential channels: current perspectives on evolution, structure, function and nomenclature | Proceedings of the Royal Society B: Biological Sciences," Jul. 2020, doi: 10.1098/rspb.2020.1309.
42. X. Yao, H.-Y. Kwan, and Y. Huang, "Regulation of TRP Channels by Phosphorylation," Neurosignals, vol. 14, no. 6, pp. 273 – 280, 2005, doi: 10.1159/000093042.
43. S. F. Pedersen, G. Owsianik, and B. Nilius, "TRP channels: An overview," Cell Calcium, vol. 38, no. 3, pp. 233 – 252, Sep. 2005, doi: 10.1016/j.cca.2005.06.028.
44. S. L. Yang, Q. Cao, K. C. Zhou, Y. J. Feng, and Y. Z. Wang, "Transient receptor potential channel C3 contributes to the progression of human ovarian cancer," Oncogene, vol. 28, no. 10, Art. no. 10, Mar. 2009, doi: 10.1038/onc.2008.475.
45. G. Shapovalov, A. Ritaine, R. Skryma, and N. Prevarskaya, "Role of TRP ion channels in cancer and tumorigenesis," Semin. Immunopathol., vol. 38, no. 3, pp. 357–369, May 2016, doi: 10.1007/s00281-015-0525-1.
46. D. Gikika and N. Prevarskaya, "TRP channels in prostate cancer: the good, the bad and the ugly?," Asian J. Androl., vol. 13, no. 5, pp. 673–676, Sep. 2011, doi: 10.1038/aaja.2011.18.
47. C. Van Haute, D. De Ridder, and B. Nilius, "TRP Channels in Human Prostate," Sci. World J., vol. 10, pp. 1597 – 1611, Aug. 2010, doi: 10.1100/tsw.2010.149.
48. C. L. So, M. J. G. Milevskiy, and G. R. Monteith, "Transient receptor potential cation channel subfamily V and breast cancer," Lab. Invest., vol. 100, no. 2, Art. no. 2, Feb. 2020, doi: 10.1038/s41374-019-0348-0.
49. V. C. Bomben, K. L. Turner, T.-T. C. Barclay, and H. Sontheimer, "Transient receptor potential canonical channels are essential for chemotactic migration of human malignant glioma," J. Cell. Physiol., vol. 226, no. 7, pp. 1879–1888, Jul. 2011, doi: 10.1002/jcp.22518.
50. N. Tajeddine and P. Gaillly, "TRPC1 protein channel is major regulator of epidermal growth factor receptor signaling," J. Biol. Chem., vol. 287, no. 20, pp. 16146 – 16157, May 2012, doi: 10.1074/jbc.M112.340034.
51. B. He et al., "Silencing TRPC1 expression inhibits invasion of CNE2 nasopharyngeal tumor cells," Oncol. Rep., vol. 27, no. 5, pp. 1548–1554, May 2012, doi: 10.3892/or.2012.1695.
52. S. L. Yang, Q. Cao, K. C. Zhou, Y. J. Feng, and Y. Z. Wang, "Transient receptor potential channel C3 contributes to the progression of human ovarian cancer," Oncogene, vol. 28, no. 10, Art. no. 10, Mar. 2009, doi: 10.1038/onc.2008.475.
53. X. Ma et al., "Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells," Proc. Natl. Acad. Sci. U. S. A., vol. 109, no. 40, pp. 16282–16287, Oct. 2012, doi: 10.1073/pnas.120989109.
54. R. Cai, G. Ren, X. Ding, Y. Wang, and Y. Jin, "[Essential role of TRPC6 in the proliferation of gastric cancer and its mechanism]," Zhonghua Zhong Liu Za Zhi, vol. 34, no. 8, pp. 577–581, Aug. 2012, doi: 10.3760/cma.j.issn.0253-3766.2012.08.004.
55. L. M. Duncan et al., "Melastatin Expression and Prognosis in Cutaneous Malignant Melanoma," J. Clin. Oncol., vol. 19, no. 2, pp. 568–576, Jan. 2001, doi: 10.1200/JCO.2001.19.2.568.
56. C. Holzmann et al., "Transient receptor potential melastatin 4 channel contributes to migration of androgen-insensitive prostate cancer cells, " Oncotarget, vol. 6, no. 39, pp. 41783–41793, Dec. 2015, doi: 10.18632/oncotarget.6157.
57. A. Hantute-Ghesquier, A. Haunstrate, N. Prevarskaya, and V. Leh‘en‘kyi, "TRPM Family Channels in Cancer," Pharmaceuticals, vol. 11, no. 2, Jun. 2018, doi: 10.3390/ph11020058.
58. R. Xie et al., "Calcium Promotes Human Gastric Cancer via a Novel Coupling of Calcium-Sensing Receptor and TRPV4 Channel," Cancer Res., vol. 77, no. 23, pp. 6499 – 6512, Dec. 2017, doi: 10.1158/0008-5472.CAN-17-0360.
59. S. Kaiser et al., "Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer," Genome Biol., vol. 8, no. 7, p. R131, 2007, doi: 10.1186/gb-2007-8-7-r131.
60. J. Xie, H. Pan, J. Yao, Y. Zhou, and W. Han, “SOCE and cancer: Recent progress and new perspectives,” Int. J. Cancer, vol. 138, no. 9, pp. 2067 – 2077, 2016, doi: https://doi.org/10.1002/ijc.29840.

61. E. D. Covington, M. M. Wu, and R. S. Lewis, “Essential Role for the CRAC Activation Domain in Store-dependent Oligomerization of STIM1,” Mol. Biol. Cell, vol. 21, no. 11, pp. 1897–1907, Jun. 2010, doi: 10.1091/mbc.E10-02-0145.

62. S. Yang, J. J. Zhang, and X.-Y. Huang, “Orai1 and STIM1 are critical for breast tumor cell migration and metastasis,” Cancer Cell, vol. 15, no. 2, pp. 124–134, Feb. 2009, doi: 10.1016/j.ccr.2008.12.019.

63. A. Vashisht, M. Trebak, and R. K. Motiani, “STIM and Orai proteins as novel targets for cancer therapy. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis,” Am. J. Physiol. - Cell Physiol., vol. 309, no. 7, pp. C457–C469, Oct. 2015, doi: 10.1152/ajpcell.00064.2015.

64. Hamill, Marty. “Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches.” Pflügers Archiv, vol. 391, no. 2, Aug. 1981, pp. 85 – 100, doi:10.1007/BF00656997.

65. A. Molleman, “Basic Theoretical Principles,” in Patch Clamping, vol. 2, John Wiley & Sons, Ltd, 2003, p. 33.

66. M. A. Gandini, A. Sandoval, and R. Felix, “Patch-Clamp Recording of Voltage-Sensitive Ca2+ Channels,” Cold Spring Harb. Protoc., vol. 2014, no. 4, pp. pdb.top066092, Apr. 2014, doi: 10.1101/pdb.top066092.

67. J. Gao, H. Zhang, P. Xiong, X. Yan, C. Liao, and G. Jiang, “Application of electrophysiological technique in toxicological study: From manual to automated patch-clamp recording,” TrAC Trends Anal. Chem., vol. 133, p. 116082, Dec. 2020, doi: 10.1016/j.trac.2020.116082.

68. P. Chen, W. Zhang, J. Zhou, P. Wang, L. Xiao, and M. Yang, “Development of planar patch clamp technology and its application in the analysis of cellular electrophysiology,” Prog. Nat. Sci., vol. 19, no. 2, pp. 153 – 160, Feb. 2009, doi: 10.1016/j.pnsc.2008.06.012.

69. L.-W. Albrecht, F. Klaus, S. Achim, and S. Arvid, “Flip the Tip: An Automated, High Quality, Cost-Effective Patch Clamp Screen,” Receptors Channels, vol. Vol 9, no. No 1, pp. 13 – 17, Dec. 2011, doi: 10.3109/10606820308257.

70. N. Fertig, R. H. Blick, and J. C. Behrends, “Whole cell patch clamp recording performed on a planar glass chip,” Biophys. J., vol. 82, no. 6, pp. 3056–3062, Jun. 2002.

71. A. Finkel, A. Wittel, N. Yang, S. Handran, J. Hughes, and J. Costantin, “Population Patch Clamp Improves Data Consistency and Success Rates in the Measurement of Ionic Currents,” J. Biomol. Screen., vol. 11, no. 5, pp. 488 – 496, Aug. 2006, doi: 10.1177/1087057106288050.